The FDA granted accelerated approval to Nuvalent’s Nelkarmi (neladalkib) Nov. 17 for adults with previously treated, locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.
The kinase inhibitor is approved for patients who previously received alectinib as their only ALK inhibitor, or at least two ALK inhibitors plus platinum-based chemotherapy, according to the FDA’s approval notice.
The approval was based on results from the phase 1/2 ALKOVE-1 trial, which evaluated the drug in two patient groups. Among 67 patients previously treated with alectinib, 49% responded to treatment, with 52% of responders maintaining their response for at least 12 months.
Among 155 patients who previously received multiple ALK inhibitors and platinum-based chemotherapy, the response rate was 32%, with 51% of responders maintaining their response for at least 12 months.
The drug’s prescribing information includes warnings for liver, kidney and eye toxicity, elevated creatine phosphokinase levels and embryo-fetal toxicity. The recommended dose is 150 mg orally once daily.
The FDA granted the application priority review. The drug also has breakthrough therapy and orphan drug designations.